Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

Northern California Retina Vitreous Associates6 enrolled

Overview

The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pseudophakic Cystoid Macular Edema,Diabetic Macular Edema

Interventions

Dexamethasone ImplantDRUG

Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * DIABETIC PATIENTS WHO DEVELOP CYSTOID MACULA EDEMA AFTER CATARACT SURGERY (WITHIN 4-10 WEEKS AFTER SURGERY * VISUAL ACUITY WORSE THAN 20/32 Exclusion Criteria: * VISUAL ACUITY WORSE THAN 20/200 * MODERATE OR SEVERE GLAUCOMA (AS DEFINED AS USING \>2 TOPICAL GLAUCOMA MEDIATIONS. * USE OF SYSTEMIC, PERIOCULAR OR INTRAOCULAR CORTICOSTEROIDS WITHIN 30 DAYS OF ENROLLMENT

Locations (1)

Northern California Retina Vitreous Associates

Mountain View, California, United States

Outcomes

Primary Outcomes

BEST CORRECTED VISUAL ACUITY (ETDRS)

Time frame: AT DAY 180

Secondary Outcomes

RETINAL THICKNESS MEASURED BY SPECTRAL DOMAIN OPTICAL TOMOGRAPHY

CENTRAL FOVEAL THICKNESS AND MACULAR VOULUME

Time frame: 90 and 180 DAYS

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.